Litiase renal cálcica
diagnóstico metabólico e tratamento médico
Palavras-chave:
Cálculos renais, Terapêutica, Metabolismo, Diagnóstico, Farmácia, CálcioResumo
Litíase renal cálcica é uma doença comum que afeta a população no mundo todo e tem alta taxa de recorrência. Diferentes alterações metabólicas podem desencadear o aparecimento de distúrbios de pedras de cálcio, como hipercalciúria, hiperoxalúria, hiperuricosúria, hipocitratúria e outros. Existem também doenças altamente prevalentes associadas à doença de cálculo de cálcio, como hipertensão, obesidade e perda de densidade óssea mineral. Para realizar prevenção e tratamento adequados, é necessário diagnóstico correto, examinando o metabolismo mineral sérico e urinário. Depois de conhecer o diagnóstico metabólico, é possível estabelecer um tratamento dietético e farmacológico que permita controlar a doença e prevenir a recorrência de cálculos biliares. Há alguns avanços no tratamento dessa doença e incluem o uso de alendronato de sódio em pacientes com nefrolitíase de cálcio e osteopenia/osteoporose, ou a combinação de um tiazídico com um bifosfonato. Em resumo, litíase renal cálcica exige, muitas vezes, um tratamento multidroga com rigorosos controle e acompanhamento de pacientes.
Downloads
Referências
Alapont Pérez FM, Gálvez Calderón J, Varea Herrero J, et al. Epidemiología de la litiasis urinaria [Epidemiology of urinary lithiasis]. Actas Urol Esp. 2001;25(5):341-9.
Bihl G, Meyers A. Recurrent renal stone disease-advances in pathogenesis and clinical management. Lancet. 2001;358(9282):651-6.
Evan AP. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol. 2010;25(5):831-41
Soucie JM, Coates RJ, McClellan W, Austin H, Thun M. Relation between geographic variability in kidney stones prevalence and risk factors for stones. Am J Epidemiol. 1996;143(5):487-95.
Arrabal Martín M, Fernández Rodríguez A, Arrabal Polo MA, Ruíz García MJ, Zuluaga Gómez A. Estudio de factores físico-químicos en pacientes con litiasis renal. [Study of the physical-chemical factors in patients with renal lithiasis]. Arch Esp Urol. 2006;59(6):583-94.
Hermida Pérez JA, Pérez Palmes MP, Loro Ferrer JF, Ochoa Urdangarain O, Buduen Nuñez A. Cólico nefrítico en el servicio de urgencias. Estudio epidemiológico, diagnostico y etiopatogénico [Renal colic at emergency departments: Epidemiologic, diagnostic andetiopathogenic study]. Arch Esp Urol. 2010;63(3):173-87.
Eliahou R, Hidas G, Duvdevani M, Sosna J. Determination of renal stone composition with dual-energy computed tomography: an emerging application. Semin Ultrasound CT MR. 2010;31(4):315-20.
Evan A, Lingeman J, Coe FL, Worcester E. Randall’s plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int. 2006;69(8):1313-8.
Evan AP, Lingeman JE, Coe FL, Worcester EM. Role of interstitial apatite plaque in the pathogenesis of the common calcium oxalate stone. Semin Nephrol. 2008;28(2):111-9.
Matlaga BR, Coe FL, Evan AP, Lingeman JE. The role of Randall’s plaques in the pathogenesis of calcium stones. J Urol. 2007;177(1):31-8.
Grases F, Costa-Bauzá A, Gomila I, Conte A. Origin and types of calcium oxalate monohydrate papillary renal calculi. Urology. 2010;76(6):1339-45.
Tsujihata M. Mechanism of calcium oxalate renal stone formation and renal tubular cell injury. Int J Urol. 2008;15(2):115-20.
Worcester EM, Coe FL. Clinical practice. Calcium kidney stones. N Engl J Med. 2010;363(10):954-63.
Lancina Martín JA. Litiasis urinaria. Presente y future. Actas Urológicas Españolas. 2005;29(4):339-44. Available from: http://www.elsevier.es/ es/revistas/actas-urologicas-españolas-292/litiasis-urinaria-presente- futuro-13144104-editoriales-2005. Accessed in 2012 (Aug 16).
Chandhoke PJ. Evaluación del formador recurrente de cálculos. Urol Clin N Am. 2007;34:315-22. Available from: http://www.elsevier.es/ sites/default/files/elsevier/pdf/507/507v34n03a13122979pdf001. pdf. Accessed in 2012 (Aug 16).
Areses Trapote R, Urbieta Garagorri MA, Ubetagoyena Arrieta M, Mingo Monge T, Arruebarrena Lizarraga D. Evaluación de la enfermedad renal litiásica. Estudio metabólico [Evaluation of renal stone disease: metabolic study]. An Pediatr (Barc). 2004;61(5):418-27.
Parmar MS. Kidney stones. BMJ. 2004;328(7453):1420-4.
Sakhaee K. Recent advances in the pathophysiology of nephrolithiasis. Kidney Int. 2009;75(6):585-95.
Park S, Pearle MS. Fisiopatología y tratamiento de los cálculos de calico. Urol Clin N Am. 2007;34:323-34. Available from: http://www. elsevier.es/sites/default/files/elsevier/pdf/507/507v34n03a13122980 pdf001.pdf. Accessed in 2012 (Aug 16).
Arrabal-Polo MA, Arrabal-Martin M, de Haro-Munoz T, et al. Mineral density and bone remodelling markers in patients with calcium lithiasis. BJU Int. 2011;108(11):1903-8; discussion 1908.
Yuen JW, Gohel MD, Poon NW, et al. The initial and subsequent inflammatory events during calcium oxalate lithiasis. Clin Chim Acta. 2010;411(15-16):1018-26.
Frick KK, Bushisnky DA. Molecular mechanisms of primary hypercalciuria. J Am Soc Nephrol. 2003;14(4):1082-95.
Stechman MJ, Loh NY, Thakker RV. Genetic causes of hypercalciuric nephrolithiasis. Pediatr Nephrol. 2009;24(12):2321-32.
Worcester EM, Coe FL. New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol. 2008;28(2):120-32.
Ossandón Salas E, Storme Cabrera O, Ledesma R, et al. Resultados del estudio metabólico en 54 pacientes con urolitiasis de alto riesgo de recurrencia [Metabolic study results of 54 patients with high risk of recurrent urolithiasis]. Actas Urol Esp. 2009;33(4):429-32.
Pak CY, Britton F, Peterson R, et al. Ambulatory evaluation of nephrolithiasis. Classification, clinical presentation and diagnostic criteria. Am J Med. 1980;69(1):19-30.
Reina Ruiz CM, Conde Sánchez JM, Domínguez Domínguez M, Espinosa Olmedo J, García Pérez M. Papel del fosfato en la litiasis cálcica recidivante. Una visión actual [Role of phosphate in recurrent calcium lithiasis: The recurrent concept]. Arch Esp Urol. 2001;54:1029-
Available from: http://pesquisa.bvsalud.org/regional/resources/ ibc-27478. Accessed in 2012 (Aug 16).
Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int. 2009;75(12):1264-71.
Hoppe B, Langman CB. A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol. 2003;18(10):986-91.
Siva S, Barrack ER, Reddy GP, et al. A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease. BJU Int. 2008;103(1):18-21.
Annuk M, Backman U, Holmgren K, Vessby B. Urinary calculi and jejunoileal bypass operation. A long-term follow-up. Scand J Urol Nephrol. 1998;32(3):177-80.
Schwille PO, Schmiedl A, Herrmann U, et al. Magnesium, citrate, magnesium citrate and magnesium-alkali citrate as modulators of calcium oxalate crystallization in urine: observations in patients with recurrent idiopathic calcium urolithiasis. Urol Res. 1999;27(2):117-26.
Bek-Jensen H, Fornander AM, Nilsson MA, Tiselius HG. Is citrate an inhibitor of calcium oxalate crystal growth in high concentrations of urine? Urol Res. 1996;24(2):67-71
Tiselius HG, Fornander AM, Nilsson MA. The effects of citrate and urine on calcium oxalate crystal aggregation. Urol Res. 1993;21(5):363-6.
Lewandowski S, Rodgers AL. Idiopathic calcium oxalate urolithiasis: risk factors and conservative treatment. Clin Chim Acta. 2004; 345(1-2):17-34.
Lancina Martín JA, Rodríguez-Rivera García J, Novás Castro S, et al. Factores de riesgo metabólico en urolitiasis cálcica según el sexo y edad de los pacientes. Actas Urológicas Españolas. 2002;26(2):111-20. Available from: http://www.elsevier.es/en/node/2079359. Accessed in 2012 (Aug 16).
Grases F, Sanchis P, Perelló J, Costa-Bauzá A. Role of uric acid in different types of calcium oxalate renal calculi. Int J Urol. 2006;13(3):252-6.
Madore F, Stampfer MJ, Rimm EB, Curhan GC. Nephrolithiasis and risk of hypertension. Am J Hypertens. 1998;11(1 Pt 1):46-53.
Madore F, Stampfer MJ, Willet WC, Speizer FE, Curhan GC. Nephrolithiasis and risk of hypertension in women. Am J Kidney Dis. 1998;32(5):802-7.
Blackwood AM, Sagnella GA, Cook DG, Cappuccio FP. Urinary calcium excretion, sodium intake and blood pressure in a multi-ethnic population: results of the Wandsworth Heart and Stroke Study. J Hum Hypertens. 2001;15(4):229-37.
Cirillo M, Ciacci C, Laurénzi M, et al. Salt intake, urinary sodium, and hypercalciuria. Miner Electrolyte Metab. 1997;23(3-6):265-8.
Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. Urol Res. 2006;34(3):193-9.
Asplin JR, Coe FL. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol. 2007;177(2):565-9.
Zerwekh JE. Bone disease and idiopathic hypercalciuria. Semin Nephrol. 2008;28(2):133-42.
Reed BY, Gitomer WL Heller HJ, et al. Identification and characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype and low spinal bone density. J Clin Endocrinol Metab. 2002;87(4):1476-85.
Gomes SA, dos Reis LM, Noronha IL, Jorgetti V, Heilberg IP. RANKL is a mediator of bone resorption in idiopathic hypercalciuria. Clin J Am Soc Nephrol. 2008;3(5):1446-52.
Sakhaee K, Maalouf NM, Kumar R, Pasch A, Moe OW. Nephrolithiasis- associated bone disease: pathogenesis and treatment options. Kidney Int. 2011;79(4):393-403.
Hall PM. Nephrolithiasis: treatment, causes, and prevention. Cleve Clin J Med. 2009;76(10):583-91.
Valle Díaz de la Guardia F, Arrabal Martín M, Arrabal Polo MA, et al. Litiasis renal en pacientes con hiperparatiroidismo primario. Evolución y tratamiento [Renal lithiasis in patients with primary hyperparathyroidism. Evolution and treatment]. Arch Esp Urol. 2010;63(1):32-40.
Arrabal Martín M, Valle Díaz de la Guardia F, Jiménez Pacheco A, et al. Tratamiento de la litiasis renal con bifosfonatos [The treatment of renal lithiasis with biphosphonates]. Arch Esp Urol. 2007;60(7):745-54.
Pak CY, Sakhaee K, Moe O, et al. Biochemical profile of stone-forming patients with diabetes mellitus. Urology. 2003;61(3):523-7.
Zimmerer T, Weiss C, Hammes HP, et al. Evaluation of urolithiasis: a link between stone formation and diabetes mellitus? Urol Int. 2009;82(3):350-5.
Tiselius HG; Advisory Board of European Urolithiasis Research and EAU Health Care Office Working Party for Lithiasis. Possibilities for preventing recurrent calcium stone formation: principles for the metabolic evaluation of patients with calcium stone disease. BJU Int. 2001;88(2):158-68.
Straub M, Hautmann RE. Developments in stone prevention. Curr Opin Urol. 2005;15(2):119-26.
Grases F, Costa-Bauza A, Prieto RM. Renal lithiasis and nutrition. Nutr J. 2006;5:23.
Fink HA, Akornor JW, Garimella PS, et al. Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials. Eur Urol. 2009;56(1):72-80.
Pietrow PR, Karellas ME. Medical management of common urinary calculi. Am Fam Physician. 2006;74(1):86-94.
Jiménez Verdejo A, Arrabal Martín M, Miján Ortiz JL, et al. Efecto del citrato potásico en la profilaxis de la litiasis urinaria [Effect of potassium citrate in the prophylaxis of urinary lithiasis]. Arch Esp Urol. 2001;54(9):1036-46.
Fernández-Rodríguez A, Arrabal-Martín M, García-Ruiz MJ, et al. Papel de las tiazidas en la profilaxis de la litiasis cálcica recidivante [The role of thiazides in the prophylaxis of recurrent calcium lithiasis]. Actas Urol Esp. 2006;30(3):305-9.
Arrabal-Martín M, Fernández-Rodríguez A, Arrabal-Polo MA, García- Ruiz MJ, Zuluaga-Gómez A. Extracorporeal renal lithotripsy: evolution of residual lithiasis treated with thiazides. Urology. 2006;68(5):956-9.
Arrabal-Polo MA, Arrabal-Martin M, Zuluaga-Gomez A. Alendronate and resorptive hypercalciuria [Alendronate and resorptive hypercalciuria]. Med Clin (Barc). 2011;137(7):333.
Bushinsky DA, Neumann KJ, Asplin J, Krieger NS. Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int. 1999;55(1):234-43.
Giusti A, Barone A, Pioli G, et al. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. Nephrol Dial Transplant. 2009;24(5):1472-7.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
